Podcasts about breast cancer research

The Trump administration's feud with major American universities escalated this week as a federal antisemitism task force notified Harvard that $450 million of the school’s research grants are being cut. That’s on top of the $2.2 billion it had previously frozen. Laura Barrón-López spoke with one of the affected researchers, Joan Brugge, director of Harvard’s Ludwig Cancer Center. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Prof Michael Kerin, Professor of Surgery at the University of Galway and Consultant Surgeon at Galway University Hospitals, discusses issues in cancer care and welcomes a €4m research investment for breast cancer.

Donna J Hopkins, a West Virginia native, Donna is the 8th child of 10 children born to the late Irving and Nazimova Hopkins. She is a graduate of Fairmont State University. She earned degrees in Radio & Television Communication and Regents of Arts. An athlete at heart, she earned scholarships in both basketball and track. After college, she moved to the Washington, D.C., metropolitan area where she currently resides.Donna is a sports television personality, she is currently a co-host/reporter on Tony McGee Pro Football Plus on Mid Atlantic Sports Net (MASN), author of Getting to the other side of Victory, Founder/CEO of a non-profit Hopkins Breast Cancer Inc., a public speaker for breast cancer awareness programs, inspirational and motivational speaker, two-time breast cancer survivor and an amputee. She is on a mission to share her triumphant journey and to teach individuals how to reset and tap into the hidden strength we all have the passions and the purposes that drive us to not only win for ourselves but for others.Honors2001, Sears, the WNBA, the Washington Mystics and NABCO National Alliance of Breast Cancer selected as the Local Breast Health Hero2011 Ambassador for Under Armour Power of Pink campaign2000-2004, spokesperson for the American Cancer SocietyServed as a board member for the Breast Cancer Care Foundation from 2000 to 20052014, Fairmont State University Outstanding Alumni award for community service2015, the Nina Hyde Center for Breast Cancer Research at Georgetown Lombardi Comprehensive Cancer Center presented Donna with the Lombardi Spirit of Life Award. The Spirit of Life award is “given to a woman who exemplifies character and leadership in promoting breast cancer research and awareness while instilling hope and a spirit of life in all who meet her.July 2017, presented by ASA Women USA the Cancer Leadership Community service award.#donnahopkins #tonymcgeefootballplus #livewithcdp #washingtoncommanders #chrispomay #barrycullenchevrolet https://beacons.ai/chrisdpomayhttps://www.cameo.com/chrispomayhttps://www.paypal.com/paypalme/chris... (tip the host) https://podcasts.apple.com/ca/podcast...Want to create live streams like this? Check out StreamYard: https://streamyard.com/pal/d/54200596...

Can people diagnosed with metastatic hormone receptor-positive breast cancer avoid chemotherapy and take a CDK4/6 inhibitor instead? Do people diagnosed with DCIS need to have surgery? Will there soon be another oral selective estrogen degrader available? Breastcancer.org medical advisor Dr. Kevin Fox explains the details of the studies and what they mean for you. Listen to the episode to hear Dr. Fox discuss these studies: Young-PEARL: Ibrance plus Aromasin, along with ovarian suppression, offers better progression-free survival than Xeloda for pre-menopausal women with metastatic hormone receptor-positive, HER2-negative breast cancer who had previously received tamoxifen. PATINA: Adding Ibrance to standard-of-care first treatments for metastatic hormone receptor-positive, HER2-positive breast cancer increased progression-free survival by more than a year. EMBER-3:Imlunestrant led to longer progression-free survival than standard therapy if the cancer had an ESR1 mutation among people with estrogen receptor-positive, HER2-negative advanced-stage breast cancer. Adding Verzenio to imlunestrant improved progression-free survival compared to imlunestrant alone, whether the cancer had an ESR1-mutation or not. COMET: Can people with low-risk DCIS just be monitored instead of having surgery with or without radiation? 

Each year in New Zealand, about 3600 people are diagnosed with breast cancer. Currently, there is no cure for the disease that affects one in nine women across their lifetime and, on average, 25 Kiwi men per year. As part of their latest fundraising effort, Breast Cancer Cure has launched the Tees for a Cure campaign - recruiting 17 popular Kiwi designers to utilise their skills for the cause. UoA cancer researcher Dr Annette Lasham says everybody involved is so committed to making a difference. "The designers are there - everybody is so committed to giving up their time and trying to make a difference for breast cancer." LISTEN ABOVESee omnystudio.com/listener for privacy information.

The National Institutes of Health (NIH) are the largest funder of cancer research in the world. A January 2025 executive order froze NIH funding and cut indirect cost payments. Another executive order halted all public communications by a number of federal agencies. Challenges to the orders are winding through the courts.  Dr. Donald McDonnell, who studies and develops drugs to treat breast and prostate cancer, explains how these actions are affecting breast cancer research and what it might mean for people diagnosed with the disease. Listen to the episode to hear Dr. McDonnell discuss: why there may be no federal money allocated to cancer research this year why all cancer research will likely stop if no federal money is allocated how the funding freeze is affecting future scientists how the freeze may affect someone who was diagnosed with breast cancer today

Hormonal birth control increases breast cancer risk in women with a BRCA1 mutation, but not women with a BRCA2 mutation. Levonorgestrel IUDs increase risk, but how much? The long-term risk of breast cancer coming back — recurring — as metastatic disease has gone down in the last 20 years, but younger women still have a higher risk than older women. What does all this mean? Breastcancer.org Professional Advisory Board member Dr. Kathy Miller discusses the details of these studies and how they may affect you. Listen to the episode to hear Dr. Miller discuss these studies: hormonal birth control ups risk of breast cancer in women with a BRCA1 mutation levonorgestrel IUDs increase risk breastfeeding after breast cancer seems safe the long-term risk of late, distant recurrence has gone down but age affects that risk

In this episode of Onc Now, Jonathan is joined by Dr Dave Cescon, a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre, Toronto, Canada. Together, they explore the transformative impact of CDK4/6 inhibitors, challenges in liquid biopsy research, and the potential of mRNA vaccines in oncology.  Timestamps: (02:44) -Swimming in Toronto: Competitive vs. Open Water  (08:06) -From Internal Medicine to Breast Cancer Research  (14:09) -Translational research and circulating tumour DNA  (19:53) -The role of CDK4/6 inhibitors in breast cancer  (29:04) -FDA approval of ribociclib for high-risk early breast cancer  (31:45) -The future of mRNA vaccines for personalised cancer care  (37:34) -Dave's research challenges and innovations  (39:13) -Three wishes for healthcare 

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD explores the complex and often controversial topic of alcohol consumption and its impact on health. From historical context to modern studies, he provides a balanced look at the potential benefits and risks of alcohol, encouraging viewers to make informed decisions based on evidence rather than emotion. Summary: Dr. Hassell discusses the nuanced role of alcohol in health and lifestyle. While heavy drinking poses clear dangers—such as liver disease, cardiovascular issues, and societal harm—low to moderate consumption might have benefits in certain contexts. Evidence from large studies suggests reduced risks of cardiovascular disease, type 2 diabetes, and some forms of dementia for moderate drinkers, particularly when paired with a healthy lifestyle. Key Takeaways: Moderation is Key: Up to 7 drinks per week for women and 10-14 for men may provide benefits, but heavy drinking is harmful. Context Matters: Alcohol's benefits are most evident in a healthy lifestyle, alongside good nutrition and regular exercise. Potential Benefits: Includes improved heart health, reduced type 2 diabetes risk, and enhanced cognitive function. Risks to Consider: Alcohol can still pose risks, including cancer, dependence, and societal harm, even at low levels. Preferred Choice: Red wine may offer additional health benefits due to its antioxidants. For more insights and advice on reducing dependence on medications through lifestyle changes, make sure to subscribe to Walk, Don't Run to the Doctor. More references can be found at www.GreatMed.org Would you like Dr. Hassell to answer your question on the air?  Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter.  We love to hear from you.  This podcast is sponsored by our generous listeners.  Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Buljeta, I., et al. (2023). Beneficial effects of red wine polyphenols on human health: comprehensive review. Current Issues in Molecular Biology, 45(2), 782–798. https://doi.org/10.3390/cimb45020052 Yoo, J. E., et al. (2022). Association between changes in alcohol consumption and cancer risk. JAMA Network Open, 5(8), e2228544. https://doi.org/10.1001/jamanetworkopen.2022.28544 Yoo JE, et al. Association between changes in alcohol consumption and cancer risk (supplemental data, tables e1 and e2). JAMA Netw Open. 2022;5(8):e2228544. doi:10.1001/jamanetworkopen.2022.28544 CDC.gov. (2024). About moderate alcohol use. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/alcohol/about-alcohol-use/moderate-alcohol-use.html#:~:text=to%20not%20drinking.-,Moderate%20drinking,or%20less%20in%20a%20day Pierre-Louis, T., et al. (2020). Effects of alcohol consumption in general, and wine in particular, on the risk of cancer development: a review. Oeno One, 54(4). https://doi.org/10.20870/oeno-one.2020.54.4.3569 Hong, S., et al. (2020). Alcohol consumption and the risk of prostate cancer: a dose-response meta-analysis. Nutrients, 12(8), 2188. https://doi.org/10.3390/nu12082188 Zhang, X., et al. (2021). Alcohol consumption and risk of cardiovascular disease, cancer and mortality: a prospective cohort study. Nutrition Journal, 20(1), 13. https://doi.org/10.1186/s12937-021-00671-y Ortola, R., et al. (2024). Alcohol consumption patterns and mortality among older adults with health-related or socioeconomic risk factors. JAMA Network Open, 7(8), e2424495. https://doi.org/10.1001/jamanetworkopen.2024.24495 Lofterod, T., et al. (2020). Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study. Breast Cancer Research and Treatment, 182(1), 215–227. https://doi.org/10.1007/s10549-020-05679-2 Tamimi, R. M., et al. (2016). Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. American Journal of Epidemiology, 184(12), 884–893. https://doi.org/10.1093/aje/kww145 Cancer.gov. (2021, July 14). Alcohol and Cancer Risk. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/risk/alcohol/alcohol-fact-sheet#how-does-alcohol-affect-the-risk-of-cancer Colditz, G. (2024). Overview of Cancer Prevention. UpToDate.com https://www.uptodate.com/contents/overview-of-cancer-prevention AICR.org. (2024, July 5). New study finds AICR/WCRF's cancer prevention recommendations are associated with reduced mortality risk from all causes, cancer and heart disease. American institute for Cancer Research. https:// www.aicr.org/news/new-study-finds-aicr-wcrfs-cancer-prevention-recommendations-are-associated-with-reduced-mortality-risk-from-all-causes-cancer-and-heart-disease/

Send us a textWhat if we told you that cancer care could be kinder to both the planet and the patient? Join us for another enlightening and educational conversation with Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson.Laugh along with Craig who, despite battling 'man flu,' sheds light on reducing the climate toxicity of cancer care. Meanwhile, Kate reassures listeners by debunking myths about the safety of oestrogens in hormone replacement therapy and IVF in patients with breast cancer, shifting focus to the real culprit—progesterone. CJ guides you through the intricacies of cross-trial comparisons in advanced melanoma, breaking down Professor Georgina Long's study on nivolumab-based therapies with a focus on the utility of propensity scores.We also spotlight initiatives aimed at improving cancer outcomes for First Nations communities in Australia, such as the introduction of cancer navigators. Dive into the latest episode of The Oncology Journal Club Podcast for a blend of humour, hope and hard-hitting discussions that promise to challenge and inspire.For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective

Minister for Further and Higher Education, Research, Innovation and Science Patrick O'Donovan TD has today announced a Research Ireland Strategic Partnership Award of €5 million to researchers at RCSI University of Medicine and Health Sciences for breast cancer research. The award will fund the 'PRISM' (Precision Oncology Research Initiative for Metastatic Breast Cancer) programme, which focuses on advanced breast cancer and aims to improve survival rates and quality of life for patients. PRISM will be led by the Beaumont RCSI Cancer Centre, with Professor Leonie Young, Scientific Director of the Beaumont RCSI Cancer Centre, serving as the Programme Director and Dr Damir Vareslija as Co-Director. Minister O'Donovan said, "I am delighted to announce this funding for PRISM, which brings together experts from the academic, pharmaceutical and charitable sectors over the next four years. Partnership is so often a critical factor in determining the success of research endeavours. I am confident that this breast cancer research collaboration will enhance understanding and treatment of this disease." The pioneering initiative, funded by Research Ireland, Breast Cancer Ireland and Carrick Therapeutics, represents a significant advancement in the fight against advanced breast cancer. Key collaborators include University College Dublin, University College Cork, University of Galway and Cancer Trials Ireland. In Ireland, more than 3,000 new cases of breast cancer are diagnosed each year, many of which progress to metastatic disease - a form that is difficult to treat. PRISM brings together a team of researchers and experts to introduce the first national longitudinal multi-omic study for advanced breast cancer patients, using comprehensive genomic profiling to better understand and target the mechanisms of breast cancer spread (metastasis) and, consequently, develop new, effective treatments. Celine Fitzgerald, Interim CEO of Research Ireland, said, "Research Ireland is proud to support PRISM through our Strategic Partnership Programme. By combining the expertise of academia, industry, and patient advocacy groups, the PRISM programme is opening the door to the prospect of more treatment options for patients with advanced breast cancer." Ash Bahl, CSO of Carrick Therapeutics, said, "Carrick Therapeutics is pleased to partner on the PRISM project. By pooling our expertise in research that aligns with our drug development strategy, we are very optimistic that this project will produce successful results." Aisling Hurley, CEO of Breast Cancer Ireland, added, "Breast Cancer Ireland is proud to co-fund the PRISM project. By supporting this innovative research, we aim to bring hope to patients and their families by working towards the discovery of newer, more effective targeted drug treatments for advanced breast cancer." Professor Fergal O'Brien, Vice Chancellor of Research and Innovation at RCSI, said, "Through this strategic partnership, our researchers are embarking on a journey that aligns with RCSI's aim to find innovative solutions that translate into new technologies for the benefit of patient health."

Kristen Dahlgren is on a mission to accelerate the development of life-saving breast cancer vaccines through her nonprofit Cancer Vaccine Coalition by gathering experts, raising awareness, and supporting promising vaccines that are already in clinical trials. TWE Host: Stacey Gualandi ========================================== Learn More about The Women's Eye Online Magazine and Podcast: Website: https://www.thewomenseye.com/  ========================================== Subscribe to The Women's Eye YouTube Channel https://www.youtube.com/user/TheWomensEye ========================================== Learn More about Kristen Dahlgren and the Cancer Vaccine Coalition Website: Cancer Vaccine Coalition https://cancervaccinecoalition.org/ Learn More About Host Stacey Gualandi: https://staceygualandi.com/ ========================================== The Women's Eye Books: 1. 20 Women Changemakers: https://amzn.to/306MAce 2. 20 Women Storytellers: https://amzn.to/3pohetF ========================================== Connect with Us: Get the Latest Updates from The Women's Eye: https://www.thewomenseye.com/subscribe/ LIKE The Women's Eye on FACEBOOK:  https://www.facebook.com/TheWomensEye/ FOLLOW The Women's Eye on TWITTER:   https://twitter.com/thewomenseye/ FOLLOW MORE on INSTAGRAM: https://www.instagram.com/thewomenseye/ ========================================== Disclaimer: Links in the description are typically affiliate links  that let you help support the channel at no extra cost.  ========================================== 

A nationwide initiative called Swim in Pink is being used to raise funds and awareness for breast cancer research. Swim In Pink is taking place this Sunday, the 27th of October at 1pm with everyone gathering at the Cappa pier, in Kilrush. To discuss this further, Alan Morrissey was joined by one of the key people behind the event, Pauline Dunleavy. Credit (c) Elements by Vector Tradition from Vectortradition via Canva

The C95 Radio Marathon for Breast Cancer Research is happening tomorrow and broadcasting live from Lawson Heights Mall in Regina throughout the day. Photographer and breast cancer survivor, Tirzah Forbes, joins Evan to discuss the work she'll be doing for the radio marathon and some of the photography work she is doing at present with breast cancer survivors.

Michael Taylor, Fund Manager for the Simplify Health Care ETF (PINK), joins Oliver Renick to talk about the fund. 100% of the net profits are donated to the Susan G. Koman Foundation for breast cancer research. Michael talks about the ways he manages the fund, and why Eli Lilly (LLY) and Purecycle Technologies (PCT) are among his top holdings for the ETF. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook – https://www.facebook.com/schwabnetwork Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

*I apologize for the audio disruptions in this episode.* In this Q&A episode, I'll be answering your questions about setting emotional boundaries, reconnecting with your partner, balancing self-love with parenting, and more. From understanding introvert-extrovert dynamics to keeping relationships strong through life's challenges, we're getting into it all. Tune in for real-life advice on navigating these important areas of life and keep the conversation going by sending in your own questions! As always shop SaraBauerBoutique.com and use code Loving15 at checkout. All October, anything PINK, 10% of proceeds go to Breast Cancer Research. --- Support this podcast: https://podcasters.spotify.com/pod/show/sara14530/support

One in eight American women will develop breast cancer in their lifetime. In this first Wellness Wednesday of Breast Cancer Awareness Month, we talk with renowned breast cancer surgeon and women's health advocate, Dr. Kristi Funk, about the latest research on prevention and the critical importance of early detection. Dr. Funk sheds light the things within our control when it comes to breast cancer risk — including diet, weight, harmful chemicals, and drinking.   See omnystudio.com/listener for privacy information.

Mona Jhaveri is a biotech scientist and entrepreneur notable for her approaches to cancer research, detection, and funding. She earned her Bachelor's Degree from SUNY Binghamton and her Doctorate in Biochemistry from the Bowman Gray School of Medicine of Wake Forest University, trained as a post-doctoral fellow at the National Cancer Institute, was granted the SPORE Fellowship Award for Breast Cancer Research at the Lombardi Cancer Center of Georgetown University, and received the Cartier Women's Initiative Award. She is the Founder of Foligo Therapeutics Inc., the Founder and Executive Director of Sound Affects, and the Founder, Executive Director, and Chairman of the Board at Music Beats Cancer. Mona makes her home in Ridgefield, Connecticut.

The U.S. Preventive Services Task Force updated its screening mammogram recommendations. Having a double mastectomy after being diagnosed with breast cancer in one breast doesn't lower the risk of dying from the disease. Certain types of exercise can reduce the risk of metastatic recurrence and neuropathy caused by chemotherapy.  What does all this mean? Breastcancer.org Professional Advisory Board member Dr. Holly Pederson discusses the details of these studies and how they may affect you. Listen to the episode to hear Dr. Pederson discuss these studies: updated U.S. Preventive Services Task Force breast cancer screening recommendations double mastectomy after a cancer diagnosis in one breast reduces the risk of cancer in the other breast, but doesn't decrease the risk of dying from breast cancer neuromuscular training reduces chemotherapy-induced peripheral neuropathy exercise reduces the risk of metastatic recurrence of hormone receptor-negative breast cancer hormonal therapy doesn't increase dementia risk Scroll down to below the “About the guest” information to read a transcript of this podcast.

Dr. Allison Zibelli and Dr. Erika Hamilton discuss the results of the DESTINY-Breast06 trial in HR+, HER2-low and HER2-ultralow metastatic breast cancer and the A-BRAVE trial in early triple-negative breast cancer, the results of which were both presented at the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Allison Zibelli: Hello, I'm Dr. Allison Zibelli, your guest host of the ASCO Daily News Podcast. I'm an associate professor of medicine and breast medical oncologist at the Sidney Kimmel Cancer Center of Jefferson Health in Philadelphia. My guest today is Dr. Erika Hamilton, a medical oncologist and director of breast cancer research at the Sarah Cannon Research Institute. We'll be discussing the DESTINY-Breast06 trial, which showed a progression-free advantage with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to chemotherapy in hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer. We'll address the implications of this study for the community, including the importance of expanding pathology assessments to include all established subgroups with HER2 expression, and the promise of expanding eligibility for antibody-drug conjugates. We'll also highlight advances in triple-negative breast cancer, focusing on the A-BRAVE trial, the first study reporting data on an immune checkpoint inhibitor avelumab in patients with triple-negative breast cancer with invasive residual disease after neoadjuvant chemotherapy.  Our full disclosures are available in the transcript of this episode.  Erika, it's great to have you on the podcast today. Dr. Erika Hamilton: Thanks so much, Allison. Happy to join. Dr. Allison Zibelli: Antibody-drug conjugates are rapidly changing the treatment landscape in breast cancer. The data from the DESTINY-Breast06 trial suggests that trastuzumab deruxtecan may become a preferred first-line treatment option for most patients with HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine therapy. First, could you remind our listeners, what's the definition of HER2-ultralow and what were the findings of this trial? Dr. Erika Hamilton: Yeah, those are fantastic questions. Ultralow really has never been talked about before. Ultralow is part of a subset of the IHC zeros. So it's those patients that have HER2-tumor staining that's less than 10% and incomplete but isn't absolutely zero. It's even below that +1 or +2 IHC that we have classified as HER2-low. Now, I think what's important to remember about D-B06, if you recall, D-B04 (DESTINY-Breast04) was our trial looking at HER2-low, is that D-B06 now included HER2-low as well as this HER2-ultralow category that you asked about. And it also moved trastuzumab deruxtecan up into the frontline. If you recall, D-B04 was after 1 line of cytotoxic therapy. So now this is really after exhausting endocrine therapy before patients have received other chemotherapy. And what we saw was an improvement in progression-free survival that was pretty significant: 13.2 months versus 8.1 months, it was a hazard ratio of 0.62. And you can ask yourself, “well, was it mainly those HER2-low patients that kind of drove that benefit? What about the ultralow category?” And when we look at ultralow, it was no different: 13.2 months versus 8.3 months, hazard ratio, again, highly significant. So I think it's really encouraging data and gives us some information about using this drug earlier for our patients with hormone receptor-positive but HER2-negative disease.  Dr. Allison Zibelli: I thought this study was really interesting because it's a patient population that I find very difficult to treat, the hormone receptor-positive metastatic patient that's not responding to endocrine therapy anymore. But it's important to mention that T-DXd resulted in more serious toxicities compared to traditional chemotherapy in this study. So how do you choose which patients to offer this to? Dr. Erika Hamilton: Yeah, those are both great points. So you're right, this is after endocrine therapy. And in fact, about 85% of these patients had received at least 2 prior lines of endocrine therapy. So I have some people kind of asking, “Well, if endocrine therapy really isn't benefiting everyone in the second-line setting post-CDK, should we just move to the ADCs?” And, no, probably we should really make sure that we're exhausting endocrine therapies for those patients that are going to benefit. And once we determine somebody has endocrine-resistant disease, that's when we would think about switching. In terms of the side effects, I think you're right. It's mainly ILD that's probably the more serious side effect that we worry about a little bit with trastuzumab deruxtecan. The good news is, through multiple trials, we've gotten a little bit better at managing this. We've pretty much all but eliminated any fatal cases of ILD, definitely less than 1% now. ILD rates, depending on what study you look for, kind of ranges in that 10% to 15% range. Any grade ILD on D-B06 was 11.3%. So really kind of making sure that we look for ILD at scans, making sure that patients are educated to tell us about any new pulmonary symptoms: cough, exertional dyspnea, shortness of breath at rest, etc. But I think the most common side effects that we really deal with on a daily basis with trastuzumab deruxtecan, luckily, is nausea, which we've gotten better at managing with the 2- or 3-drug antiemetic regimen, and probably a little bit of fatigue as well. Dr. Allison Zibelli: Thank you. So, I think for most people in the community, the sticking point here will be expanding pathology assessments to include all of the subgroups, including the ultralow. Most patients in the community are not testing for HER2-low and HER2-ultralow now. Dr. Erika Hamilton: Historically, we kind of all did HER2 IHC, right? And then as FISH became available, there were a lot of institutions that moved to FISH and maybe didn't have IHC anymore. And now, at least in my institution, we do both. But I think it's a very important point that you made that IHC was really designed to pick out those patients that have HER2-high, the 3 pluses or the FISH amplified cases. It was not to tell the difference between a 1+ or a 2+ or a 0 that's not quite a 0 and a 1+. So I think you're right. I think this is tough. I probably have a little bit more of an interesting take on this than some people will. But data from ASCO, not this year but in 2023, there was actually a pretty eloquent study presented where they looked at serial biopsies in patients, and essentially, if you got up to 4 or 5 biopsies, you were guaranteed to have a HER2-low result. Now, this didn't even include ultralow, which is even easier. If we know we include ultralow, we're really talking about probably 85% to 90% of our patients now that have some HER2 expression. But if we biopsy enough, we're guaranteed to get a HER2 low.  And so I think the question really is, if we know IHC wasn't really designed to pick out these ultralows, and we know kind of greater than 90% of patients are going to have some expression, did we kind of develop this drug a little bit backwards? Because we thought we understood HER2, and the reality is this drug is a little bit more like a sacituzumab govitecan, where we don't test for the TROP2. Should we really be kind of serial biopsying these patients or should maybe most patients have access to at least trying this drug?  Dr. Allison Zibelli: So I don't think that most of my patients will really be happy to sign up for serial biopsies. Dr. Erika Hamilton: Agreed. Dr. Allison Zibelli: Do we have any emerging technologies for detecting low levels of HER2? You talked about how the IHC test isn't really designed to detect low levels of HER2. Do you think newer detection techniques such as immunofluorescence will make a difference, or will we have liquid biopsy testing for this? Dr. Erika Hamilton: Yeah, I think liquid biopsy may be a little bit hard, just because some of those circulating tumor cells are more of a mesenchymal-type phenotype and don't necessarily express all of the same receptors. Normally, if they're cytokeratin-positive, they do, but certainly there is a lot out there looking at more sensitive measures. You mentioned immunofluorescence, there are some even more quantitative measures looking at lower levels of HER2. I definitely think there will be. I guess, ultimately, with even the IHC zeros that are the less than 10% incomplete staining, having a PFS that was absolutely no different than the HER2 low, I guess the question is, how low can we really go? We know that even the IHC zeros doesn't mean that there's no HER2 expression on the cell surface. It just means that maybe there's a couple of thousand as opposed to 10,000 or 100,000 copies of HER2. And so it really appears that perhaps this drug really is wedded to having a lot of HER2 expression. So ultimately, I wonder how much we're going to have to use those tests, especially with what we know about tumor heterogeneity. We know that if we biopsy 1 lesion in the liver, biopsy a lymph node, or even another lesion in the liver, that the HER2 results can have some heterogeneity. And so ultimately, my guess is that most people have some HER2 expression on their breast cancer cells. Dr. Allison Zibelli: So maybe we're going to be using this for everybody in the future. Dr. Erika Hamilton: It certainly seems like we keep peeling back the onion and including more and more patients into the category that are eligible to receive this. I agree. Dr. Allison Zibelli: Let's move on to triple-negative breast cancer, namely the A-BRAVE trial. This was an interesting trial for patients that did not get neoadjuvant immunotherapy and testing 2 groups. The first group was those with residual disease after neoadjuvant conventional chemotherapy. The second group was people with high-risk disease identified upfront that had upfront surgery. The study found that adjuvant avelumab did not improve disease-free survival versus observation, which was the study's primary endpoint. But interestingly, there was a significant improvement in 3-year overall survival and distant disease-free survival. Can you give us your thoughts on that? Dr. Erika Hamilton: Yeah, I think this study was really interesting. Right now, the standard for our patients with larger or node-positive triple-negative cancers is KEYNOTE-522. It's a pretty tough regimen. It's kind of 2 sequential uses of 2 chemotherapies, so 4 chemotherapy agents total with pembrolizumab. But you're right, this study looked at those that had residual disease after neoadjuvant that didn't include immunotherapy, or those patients that didn't get neoadjuvant therapy, went to surgery, and then were receiving chemotherapy on the back end. I'm going to give you the numbers, because you're right. The 3-year disease-free survival rates were not statistically significant. It was 68.3% among those that had avelumab, 63.2% with those that had observation only. So the difference was 5.1% in favor of avelumab, but it wasn't statistically significant. A p value of 0.1, essentially. But when we looked at the 3-year overall survival rates, we saw the same pattern, those patients with the avelumab doing better, but it was 84.8% overall survival and not, unfortunately, dying, versus 76.3%. So the magnitude of benefit there was 8.5%, so about 3% higher than we saw for disease-free survival, and this was statistically significant.  So is this going to change practice for most patients? I probably don't think so. I think for our patients that have larger tumors that's recognized upfront or have node positivity, we're probably going to want to use neoadjuvant chemo. Being able to get a PCR is very prognostic for our patients and enables us to offer things on the back end, such as PARP inhibitors or further chemotherapy of a different type of chemotherapy. But for our patients that go to surgery and maybe the extent of their disease just isn't recognized initially, this could be an option. Dr. Allison Zibelli: I agree. I think this will be a really useful regimen for patients where we get the surprise lymph node that we weren't expecting, or somebody who comes to us, maybe without seeing the medical oncologist, who got upfront surgery. So I thought this was really interesting. What kind of translational studies do you think we're going to do to try and understand which patients would benefit from avelumab? Dr. Erika Hamilton: Yeah, I think that's a great question, and honestly, it's a question that we haven't really answered in the neoadjuvant setting either. Immunotherapy in breast cancer is just a little bit different than it is in some other diseases. We have a benefit for those patients that are PD-L1 positive in the first line. We really haven't seen benefit for metastatic outside of first line. And then in neoadjuvant, it was among all comers. We don't have to test for PD-L1. And now we have this avelumab data from A-BRAVE. I think the question is, is there's probably a subset of patients that are really getting benefit and a subset that aren't. And I don't know that PD-L1 testing is the right test. We know a lot of people are looking at TILs, so kind of lymphocytes that are infiltrating the tumor, a variety of other kind of immunologic markers. But my guess is that eventually we're going to get smart enough to tease out who actually needs the immunotherapy versus who isn't going to benefit. But we're not quite there yet. Dr. Allison Zibelli: Thank you, Erika, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Erika Hamilton: Thanks so much for having me.  Dr. Allison Zibelli: And thank you to our listeners for joining us. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you value our insights, please take a moment to rate, review, and subscribe wherever you get your podcasts. It really helps other people to find us. So thank you very much for listening today.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    Find out more about today's speakers:  Dr. Allison Zibelli Dr. Erika Hamilton @ErikaHamilton9   Follow ASCO on social media:  @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures: Dr. Allison Zibelli:  None Disclosed   Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Krystle Zuniga PhD, RD, CSO, LDAssistant Professor of Instruction, Department of Nutritional Sciences, University of Texas at Austin.Owner, Cancer Nutrition HQ.Krystle is an experienced clinician, educator, scientist, and science communicator. Her research in the area of nutrition, physical activity, and cancer has been published in Cancer Prevention Research, Journal of Nutrition, Nutrition and Cancer, and Breast Cancer Research and Treatment. In addition to her current position as Assistant Professor of Instruction in the Department of Nutritional Sciences at University of Texas at Austin, she is a board certified oncology dietitian and owner of the private practice and social media account Cancer Nutrition HQ, where she strives to combat misinformation, share the latest research in nutrition and cancer, and translate the science into everyday actions cancer survivors can take to support their health and quality of life with nutrition. Krystle is also a founding board member of the Moving Beyond Cancer Collaborative, a non-profit that provides accessible and affordable integrative oncology health and wellness services.

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.Presenters:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasAditya Bardia, MD, MPH, FASCOProfessor of MedicineGeffen School of Medicine at UCLADirector, Breast Oncology ProgramAssistant Chief (Translational Research)Division of Medical OncologyDirector of Translational Research IntegrationUCLA Health Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaSarah Sammons, MDAssistant Professor of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston, Massachusetts Link to full program:https://bit.ly/46hLGcM

Drs. John Sweetenham and Angela DeMichele discuss potentially ground-breaking abstracts in breast and lung cancer as well as notable research on artificial intelligence and its impact on cancer care, all of which were featured at the 2024 ASCO Annual Meeting.  TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham from UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast. My guest today is Dr. Angela DeMichele, the Marianne and Robert McDonald Professor in Breast Cancer Research and co-leader of the Breast Cancer Program at the University of Pennsylvania's Abramson Cancer Center. Dr. DeMichele also served as the chair of the 2024 ASCO Annual Meeting Scientific Program. Today, she'll be sharing her reflections on the Annual Meeting and we'll be highlighting some advances and innovations that are addressing unmet needs and accelerating progress in oncology.  Our full disclosures are available in the transcript of this episode.  Dr. DeMichele, congratulations on a very robust and highly successful program at ASCO24, and thanks for joining us on the podcast today. Dr. Angela DeMichele: Well, thanks so much for having me, Dr. Sweetenham. It's a pleasure to be here.  Dr. John Sweetenham: The presidential theme of the Annual Meeting this year was the "The Art and Science of Cancer Care: From Comfort to Cure." And this was certainly reflected throughout the meeting in Chicago that welcomed more than 40,000 attendees from across the globe. I know our listeners will be interested to hear some of your own reflections from the meeting now that we're on the other side of it, so to spea  Dr. Angela DeMichele: Yes. Well, I will say that playing this role in the annual meeting really was a highlight of my career, and I feel so fortunate to have had the opportunity to do it. We had over 200 sessions, and in many, if not all of these sessions, we really tried to make sure that there was a case that really sort of grounded the session to really help people understand: you're going to hear about science, but how are you going to apply that? Who is the patient for whom this science really is important?  We had over 7,000 abstracts submitted, and our 25 tracks and their chairs really pulled through to find really the best science that we could present this year. I think what you saw really was a representation of that across the board: incredible advances in lung cancer, breast cancer, melanoma, GI cancers; also really cutting-edge technologies: AI, as we'll talk about in a little while circulating markers like ctDNA, new drug development, new classes of drugs. So it was really an exciting meeting. I mean, some highlights for me, I would say, were certainly the Plenary, and we can talk a little bit about that. Also, we had a fantastic ASCO/AACR Joint Session on “Drugging the “Undruggable Target: Successes, Challenges, and the Road Ahead.” And, if any of the listeners have not had a chance to hear this, it's really worth going in and watching this because it really brought together three amazing speakers who talked about the successes in KRAS, and then really, how are we using that success in learning how to target KRAS to now targeting a variety of other previously thought to be undruggable targets. I learned so much. And there's really both the academic and the pharma perspective there. So I'd really encourage watching this session. The other session that I really thought was terrific was one that I was honored to chair, which was a fireside chat (“How and Where Will Public Investment Accelerate Progress in Oncology? A Discussion with the NIH and NCI Directors”) with both Dr. Monica Bertagnolli, who is the director of the NIH, and Dr. Kim Rathmell, who's now the director of the NCI. And boy, I'll tell you, these two incredibly smart, thoughtful, insightful women; it was a great conversation. They were really understanding of the challenges we face conducting research, practicing medicine. And maybe different from leadership at the NIH in the past, they've really taken the approach to say that everything they do is focused on the patient, and they don't limit themselves to just research or just science, that everything that the NIH does, and particularly the NCI does, really has to be focused on making sure we can give patients the best possible care. And I think they're being very thoughtful about building important infrastructure that's going to take us into the future, incorporating AI, incorporating new clinical trial approaches that are going to make it faster and easier to conduct clinical trials and to get the results that we need sooner. So just a few of the highlights, I think, from some really interesting sessions. Dr. John Sweetenham: It certainly was an extremely enriching and impactful ASCO24. And I think that the overall theme of the meeting was extremely well reflected in the content with this amazing mix of really, truly impactful science, along with a great deal of patient-centered healthcare delivery science to accompany it. So, I completely agree with you about that. There was a lot, of course, to take in over the five days of the meeting, but I'm sure that our listeners would be very interested to hear about one or two abstracts that really stood out for you this year.  Dr. Angela DeMichele: Sure. I'm a breast cancer specialist, so I can't help but feel that the late breaking abstract, the DESTINY-Breast06 trial, was really important for the field of breast cancer. So just briefly, this is a study of the antibody drug conjugate T-DxD, trastuzumab deruxtecan. This is a drug that is actually now approved in metastatic breast cancer, really effective in HER2-positive disease. But the question that this trial was trying to answer is, can this drug, which is built with the herceptin antibody against HER2, then linked to a chemotherapeutic molecule, can this work even in the setting of very, very low HER2 expression on a tumor? I think this is an incredibly important question in the field of antibody drug conjugates, of which there are now many across diseases, is how much of the target do you really need to have on the surface of the tumor?  We had seen previously HER2 overexpressing tumors respond really well to this drug. HER2 tumors that have an intermediate level of expression were tested in the DP04 trial, and we saw that even those 2+ intermediate tumors responded well to this drug. The DP06 trial that was presented at ASCO was looking at this group of patients that have even less HER2 on the surface. So we typically measure HER2 by immunohistochemistry as 0, 1+, 2+, or 3+. And this was looking at patients whose tumors were over 0, but were at 1+ or below, so low and ultra-low. And it turned out that compared to treatment of physician's choice, the drug really had quite a lot of activity, even in these patients who have very little HER2 on their tumors, really showing progression-free survival benefits in the HER2-low and HER2-ultra-low groups that were appreciable on the order of about 5 months, additional progression free survival hazard ratios around 0.6, so really demonstrating that utilizing an antibody drug conjugate, where you've got very little target, can still be a way to get that drug to a tumor.   And I think it'll remain to be seen whether other ADCs can have activity at very low levels of IHC expression of whatever target they're designed against. I think one of the tricky things here for implementing this in breast cancer will be how do pathologists actually identify the tumors that are ultra-low because it's not something that we typically do. And so we'll go through a period, I think, of adjustment here of really trying to understand how to measure this. And there are a bunch of new technologies that I think will do a better job of detecting low levels of the protein on the surface of the tumor because the current IHC test really isn't designed to do that. It was only designed to be focused on finding the tumors that had high levels. So we have some newer technologies with immunofluorescence, for example, that can really get down to very low levels. And I think this is going to be a whole new area of ADCs, target detection – how low can you go to still see activity? So I thought that this was an important abstract for many reasons.  I will just say the second area that I was really particularly impressed with and had a big impact on me were the two lung cancer abstracts that were presented in the Plenary, the LAURA trial (LBA4) and the ADRIATIC trial (LBA5). And I think, I've been in the field of oncology for 30 years now, and when I started in the late ‘90s, lung cancer was a disease for which we had very few treatments. If we didn't catch it early and surgery wasn't possible for non-small cell lung cancer, really, it was a horrible prognosis. So we knew this year was the 20th anniversary of the discovery of EGFR as a subtype of lung cancer. That was really, I think, a turning point in the field of non-small cell lung cancer – finding a target. And now seeing the LAURA trial show that osimertinib really had such an enormous impact on progression-free survival amongst these patients who had EGFR-positive non-small cell lung cancer, progression-free survival hazard ratio of 0.16; there was a standing ovation.  And one of the really big privileges of being the Scientific Program Chair is getting to moderate the Plenary Session, and it's a really amazing experience to be standing up there or sitting there while the presenter is getting a standing ovation. But this was well deserved because of the impact this is having on patients with EGFR positive lung cancer. And it was similar with the ADRIATIC trial, which looked at the benefits of adding immunotherapy in limited-stage small-cell lung cancer. Again, a disease that treatment has not changed in 30 years, and so the addition of durvalumab to the standard backbone of chemotherapy for small cell lung cancer had its survival advantage. These patients are living longer and it was really an impressive improvement. And I think it really underscores just the revolution that has happened in lung cancer between targeted therapy and immunotherapy has completely changed the prognosis for patients with this disease. So to me, these were really landmark reports that came out at ASCO that really showed us how far we've come in oncology. Dr. John Sweetenham: Yeah, absolutely. I think that, as you mentioned, those results are truly remarkable, and they reflect extraordinary advances in science. I think we see that both in terms of the therapeutic arena, but also, I think we've started to see it in other areas as well, like symptom control, remote patient monitoring, and so on and so forth, where some of the newer virtual technologies are really having major impacts as well. Dr. Angela DeMichele: Yes, we really wanted to have a focus on artificial intelligence in this meeting, because it's having such an enormous impact on our field in everything from care delivery to diagnostics. I'd love to hear what you thought was the most interesting, because there really was just new data across the board presented. Dr. John Sweetenham: I've actually chosen 3 abstracts which I thought were particularly interesting for a couple of reasons, really. They're all based on virtual health interventions, and I think they're interesting in really reflecting the theme of the meeting, in that they are extremely advanced technology involved in the virtual platforms, a couple of which are artificial intelligence, but very impactful to patients at the same time in terms of remote symptom control, in terms of addressing disparities, and in one case, even influencing survival. So I thought these were three really interesting abstracts that I'll walk the listeners through very quickly.  The first of these was a study, Abstract 1500 (“National implementation of an AI-based virtual dietician for patients with cancer”) which looked at an artificial intelligence-based virtual dietitian for patients with cancer. This is based on the fact that we know nutritional status to be a key driver of patient experience and of cancer outcomes. And as the authors of the presentation noted, 80% of patients look for nutritional support, but many of them don't get it. And that's primarily a workforce issue. And I think that's an important thematic point as well, that these new technologies can help us to address some of the workforce issues we have in oncology. So this was an AI-based platform developed by experts in nutrition and cancer patients, based on peer reviewed literature, and a major effort in terms of getting all of these data up together. And they developed an artificial intelligence platform, which was predominantly text message based. And this platform was called INA. And as this is developing as a platform, there's a machine learning component to it as well. So in theory, it's going to get better and better and better over time.  And what they did in their study was they looked at little over 3,000 patients across the entire country who were suffering from various types of cancer, GU, breast, gynecological malignancy, GI and lung. And most of them had advanced-stage disease, and many of them had nutritional challenges. For example, almost 60% of them were either overweight or obese by BMI. And the patients were entered into a text exchange with the AI platform, which would give them advice on what they should eat, what they shouldn't eat. It would push various guidance and tips to them, it would develop personalized recipes for them, and it would even develop menu plans for the patients. And what's really interesting about this is that the level of engagement from the patients was very high, with almost 70% of patients actually texting questions to this platform. About 80% of the patients completed all of the surveys, and the average time that patients interacted with the platform was almost nine months, so this was remarkable levels of engagement, high levels of patient satisfaction. And although at this point, I think it's very early and somewhat subjective, there was certainly a very positive kind of vibe from patients. Nearly 50% have used the recommended recipes. More than 80% of them thought that their symptoms improved while they were using this platform. So I think as a kind of an assistant for remote management of patients, it's really remarkable. And the fact that the level of engagement was so high also means that for those patients, it's been very impactful.   The second one, this was Abstract 100 (“AI virtual patient navigation to promote re-engagement of U.S. inner city patients nonadherent with colonoscopy appointments: A quality improvement initiative”) looked again at an AI-based platform, which in this case was used in an underserved population to address healthcare disparities. This is a study from New York which was looking at colorectal cancer screening disparities amongst an underserved population, where historically they've used skilled patient navigators to address compliance with screening programs, in this case specifically for colorectal cancer. And they noticed in the background to this study that in their previous experience in 2022, almost 60% of patients either canceled or no-showed for colonoscopy appointments. And because of this and because of the high burden of patients that this group has, they decided to take an AI-based virtual patient navigator called MyEleanor and introduce this into their colorectal cancer screening quality improvement.  And so they introduced this platform in April of 2023 through to the end of the year, and their plan was to target reengagements of around 2,500 patients who had been non adherent with colonoscopy appointments in a previous year. And so the platform MyEleanor would call the patients to discuss rescheduling, it would assess their barriers to uptake, it would offer live transfer to somebody to schedule for them, and then it would go on closer to the point of the colonoscopy to call the patients and give them advice about their prep. And it was very nuanced. The platform would speak in both English and Spanish versions. It could detect nuances in the patient's voice, which might then trigger it to refer the patient to a live agent rather than the AI platform. So, very sophisticated technology. And what was most interesting about this, I think, was that over the eight months of the study, around 60% of patients actually engaged with this platform, with almost 60% of that group, or 33% overall, accepting a live transfer and then going on to scheduling, so that the completion rate for the no show patients went from 10% prior to the introduction of this platform to 19% after it was introduced. So [this is] another example, I think, of something which addresses a workforce problem and also addresses a major disparity within cancer care at the moment by harnessing these new technologies. And I think, again, a great interaction of very, very high-level science with things that make a real difference to our patients.  So, Dr. DeMichele, those are a couple of examples, I think, of early data which really are beginning to show us the potential and signal the impact that artificial intelligence is going to have for our patients in oncology. I wonder, do you have any thoughts right now of where you see the biggest impact of artificial intelligence; let's say not in 20 years from now, but maybe in the next year or two?  Dr. Angela DeMichele: Well, I think that those were two excellent examples. A really important feature of AI is really easing the workload on physicians. And what I hope will happen is that we'll be able to use AI in the very near future as a partner to really offload some of the quite time-consuming tasks, like charting, documentation, that really take us away from face-to-face interaction with patients. I think this has been a very difficult period where we move to electronic medical records, which are great for many reasons, but have really added to the burden to physicians in all of the extra documentation. So that's one way, I think, that we will hope to really be able to harness this. I think the other thing these abstracts indicate is that patients are very willing to interact with these AI chatbots in a way that I think, as you pointed out, the engagement was so high. I think that's because they trust us to make sure that what we're doing is still going to be overseen by physicians, that the information is going to get to us, and that they're going to be guided. And so I think that in areas where we can do outreach to patients, reminders, this is already happening with mammograms and other sorts of screening, where it's automated to make sure you're giving reminders to patients about things that they need to do for some of their basic health maintenance. But here, really providing important information – counseling that can be done by one of these chatbots in a way that is compassionate, informative and does not feel robotic to patients.   And then I was really impressed with, in the abstract on the screening colonoscopy, the ability of the AI instrument to really hear nuances in the patient's responses that could direct them directly to a care provider, to a clinician, if they thought that there might be some problem the patient was experiencing. So again, this could be something that could be useful in triaging phone calls that are coming in from patients or our portals that just feel like they are full of messages, no matter how hard you try to clear them all out, to get to them all. Could we begin to use AI to triage some of the more mundane questions that don't require a clinician to answer so that we can really focus on the things that are important, the things that are life threatening or severe, and make sure that we're getting to patients sooner? So there's just a few ways I really hope it'll help us. Dr. John Sweetenham: Yeah, absolutely. I think we're just scratching the surface. And interestingly enough, in my newsfeed this morning through email, I have an email that reads, “Should AI pick immunotherapy combinations?” So we'll see where that goes, and maybe one day it will. Who knows? Dr. Angela DeMichele There was a great study presented at ASCO about that very thing, and I think that is still early, but I could envision a situation where I could ask an AI instrument to tell me all of the data around something that I want to know about for a patient that could deliver all of the data to me in real time in the clinic to be able to help me make decisions, help me quote data to patients. I think in that way it could be very, very helpful. But it'll still need the physicians to be putting the data into context and thinking about how to apply it to the individual person. Dr. John Sweetenham: Absolutely, yes. And so just to round off, the final abstract that caught my eye, which I think kind of expands on a theme that we saw at an ASCO meeting two or three years ago around the impact of [oncology] care at home, and this was Abstract 1503 (“Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment”). So, a virtual platform but not AI in this case. And this was a study that looked at the use of an Integrative Medicine at Home virtual mind-body fitness program. And this was a platform that was used to look at hospital admission and acute care of patients who used it, and also looked at survival, interestingly enough. So what was done in this study was a small, randomized study which looked at the use of virtual live mind, body and fitness classes, and compared this in a randomized fashion to what they called enhanced usual care, which essentially consisted of giving the patients, making available to the patients, some pre-recorded online meditation resources that they could use. And this was applied to a number of patients with various malignancies, including melanoma, lung, gynecologic, head and neck cancers, all of whom were on systemic therapy and all of whom were reporting significant fatigue.  This was a small study; 128 patients were randomized in this study. And what was very interesting, to cut to the chase here, is that the patients who had the virtual mind-body program, compared with the control group, actually were less likely to be hospitalized, the difference there being 6.3% versus 19.1%, respectively. They spent fewer days in the hospital. And remarkably, the overall survival was 24.3 months median for patients in the usual care arm and wasn't reached in those patients who were on the virtual mind-body fitness class platform. So very preliminary data, certainly are going to need more confirmation, but another example of how it appears that many of these non-pharmacological interventions have the potential to improve meaningful endpoints, including hospital stays and, remarkably, even survival. So again, I think that that is very consistent with the theme of this year's meeting, and I found that particularly interesting, too.  I think our time is up, so I want to thank you, Dr. DeMichele, for sharing your insights with us today on the ASCO Daily News Podcast. We really appreciate it. And once again, I want to congratulate you on what was really a truly remarkable ASCO this year.  Dr. Angela DeMichele: Well, thanks so much for having me. It's been a tremendous pleasure to be with you today. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in a transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn      Disclosures:   Dr. John Sweetenham:   Consulting or Advisory Role: EMA Wellness  Dr. Angela DeMichele: Consulting or Advisory Role (an immediate family member): Pfizer Research Funding (Inst.): Pfizer, Genentech, Novartis, Inviata/NeoGenomics  

On today's episode, Paul and Charlie are joined by former England international Darren Bent, to discuss all things England after their win over Serbia. Laura Smyth opens up about her challenges with breast cancer and how you can raise money for Breast Cancer Research. Finally, talkSPORT's Shebahn Aherne joins from the Scotland camp ahead of their clash against Switzerland! Hosted on Acast. See acast.com/privacy for more information.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting featured five days of presentations and educational sessions on all types of cancer. Dr. Eleonora Teplinsky, a board-certified medical oncologist at the Valley-Mount Sinai Comprehensive Cancer Center in Paramus, NJ, summarizes the top breast cancer research. Listen to the episode to hear Dr. Teplinsky explain: the DESTINY- Breast06 study on Enhertu compared to chemotherapy for metastatic hormone-receptor-positive breast cancer how circulating tumor DNA may help predict recurrence descalating treatment to reduce the risk of side effects

Last year, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, served as co-chair of i3 Health's webinar and online activity, Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC). With numerous advances in TNBC research occurring since then, Dr. Tolaney sat down with Oncology Data Advisor to share additional updates from clinical trials and a preview into the future of treatment with emerging therapies for TNBC.

On this episode of the Bench to Bedside podcast, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down for a conversation with Camy Crank, author of the book “Hair Today, Gone Tomorrow: What I Lost and Gained Through Breast Cancer.” Camy's own breast cancer journey began in 2015, when a second opinion from KU Cancer Center showed stage 3B disease. In 2020, she learned her cancer had metastasized. Camy is also a member of KU Cancer Center's patient research advocacy group, PIVOT, where she has been able to contribute to cancer research through providing the patient perspective. Listen as Camy shares her cancer journey, why writing about the experience was important to her and her family, and what she has learned along the way. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode:  Purchase Camy's book, "Hair Today, Gone Tomorrow: What I Lost and Gained Through Breast Cancer" Learn more about breast cancer screening at KU Cancer Center Learn more about cancer metastasis Become a member of PIVOT, KU Cancer Center's patient research advocacy program

When Stephanie Graff was a breast oncology fellow in 2010, one of her patients brought a marked up copy of “Dr. Susan Love's Breast Book” to an appointment. “One of my patients had brought it in and was using it almost as her cancer notebook, and had pages flagged and said, 'Well, what about this? What about this? It says here…,'” Graff, director of Breast Oncology at Lifespan Cancer Institute and medical advisor for the Dr. Susan Love Foundation for Breast Cancer Research, said to The Cancer Letter. It was the first time that the book, written by Susan Love, a breast cancer surgeon, activist, and founder of the Dr. Susan Love Foundation for Breast Cancer Research, had shown up on Graff's radar. “Dr. Susan Love's Breast Book” was first published in 1990. Now, Graff is a contributing author of the seventh edition, the most recent version of the book published in 2023. Graff spoke with Alexandria Carolan, associate editor of the Cancer History Project. A full transcript of this conversation, including how Graff came to know and work with Susan Love, appears on the Cancer History Project.

Laura Sage, the founder of the Lynn Sage Breast Cancer Foundation, joins Lisa Dent to discuss how the University of Chicago Medicine, RUSH University for Health, and Northwestern Medicine all came together to launch the Chicago Breast Cancer Research Consortium as a way to increase access to clinical trials for breast cancer research. Follow The Lisa […]

In this episode, Josh interviewed Dr Ann Partridge, the director of the adult survivorship program at the Dana-Farber Institute. She is the co-founder and director of the Program for Young Women with Breast Cancer and is passionate about communication, risk perception and behavioural aspects of cancer care. Dr Partridge is the principal investigator for the Young Women's Breast Cancer study, which has currently enrolled over 1300 women throughout the United States, and has chaired both ASCO's scientific program committee and the ESMO-sponsored Breast Cancer in Young Women Conference. In 2018, Dr Partridge was recognized with the American Association for Cancer Research's Outstanding Investigator Award for Breast Cancer Research.The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.The Kinghorn Cancer Centre: https://tkcc.org.au/Dana Farber Cancer Institute: https://www.dana-farber.org/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow. Hosted on Acast. See acast.com/privacy for more information.

Following her mother's passing Shari Lewis in 1998, Mallory began appearing with Lamb Chop at live and televised events, entertaining at thousands of venues as varied as the State Fairs, Performing Arts Centers, Cruise Ships and @ Military Bases around the world. Mally and Lamb Chop LOVE touring with the USO, entertaining the troops and their families, in fact Lamb Chop was recently “pinned” by a Marine General, and now makes Mally salute her before every show! Mally and Lamb Chop have received many performance awards including the “Award for Excellence by UNAMA”, the “International Puppeteers Association”, and “Kid's First Palmer Vision Award”. As an author, Mallory has penned 20 children's novels, and is a multiple “Emmy Award Nominee” and Emmy Award Winner” for “Outstanding Writing in a Children's Series”. Mallory and Lamb Chop have organized 4 Women's World Record Skydiving Events which have raised close to 2 million dollars for Breast Cancer Research (jumpforthecause.com) and though Mallory stays on the ground these days, Lamb Chop proudly holds a USPA license and 4 records! Lamb Chop and Mally will soon be celebrating over 20 years together as performers, and their three shows: “A Very Lamb Chop Holiday” (adaptable to ALL holidays), “Lamb Chop Loves America” (a curriculum show focusing on American History for Primary and Lower Schools), and “A Lamb Chop Celebration-a Legacy Show “, featuring a hour plus of Lamb Chop Live seamlessly melded with vintage footage and nostalgia delights audiences of ALL ages. All shows offer full video backdrops, music, comedy, dancing, sing-a-longs, audience participation and more! Join Shari's daughter, Mallory Lewis and YOUR childhood pal Lamb Chop and enjoy sharing the memories with your children and grandchildren! Web: https://mallorylewisandlambcho... Atlanta Jewish Film Festival: https://ajff.org/festival-seri... About the show: Ash Brown is a gifted American producer, blogger, speaker, media personality and event emcee. The blog on AshSaidit.com showcases exclusive event invites, product reviews and so much more. Her motivational podcast "The Ash Said It Show" is available on major media platforms such as iTunes, Spotify, iHeart Radio & more. This program has 1900+ episodes and over half a million streams worldwide. She uses these mediums to motivate & encourage her audience in the most powerful way. She keeps it real! ► Luxury Women Handbag Discounts: https://www.theofficialathena.... ► Become an Equus Coach®: https://equuscoach.com/?rfsn=7... ► For $5 in ride credit, download the Lyft app using my referral link: https://www.lyft.com/ici/ASH58... ► Review Us: https://itunes.apple.com/us/po... ► Subscribe: http://www.youtube.com/c/AshSa... ► Instagram: https://www.instagram.com/1lov... ► Facebook: https://www.facebook.com/ashsa... ► Twitter: https://twitter.com/1loveAsh ► Blog: http://www.ashsaidit.com/blog #atlanta #ashsaidit #theashsaiditshow #ashblogsit #ashsaidit®Become a supporter of this podcast: https://www.spreaker.com/podcast/the-ash-said-it-show--1213325/support.

In today's episode we are joined by Dr David Harper to explore the latest in ketogenic breast cancer research. We specifically speak to his recently published study, ‘Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-Care trial'. As well as unpacking what it takes to conduct a trial of this experimental design, we look at what improvements can be obtained with both 3 and 6 months in nutritional ketosis, including blood ketone levels, blood glucose levels, insulin levels, body fat percentage and more.   Head to https://www.stephlowe.com/podcasts/469 for show notes, episode transcripts and more.

The Quicky evening news update for Monday, 15 January 2024. The Quicky is the easiest and most enjoyable way to get across the news every day. And it's delivered straight to your ears in a daily podcast so you can listen whenever you want...at the gym, on the train, in the playground or at night while you're making dinner. Want The Quicky in your ears every day? Listen on Spotify... https://open.spotify.com/show/4omeoOVsGWXhhFObFWGTvT CREDITS  Host: Isabella Ross Producer: Kally Borg Audio Producer: Thom LionBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

This educational podcast will provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of Triple-negative breast cancer (TNBC).   Launch Date: November 9, 2023Release Date: November 9, 2023Expiration Date: October 31, 2024   ACTIVITY DESCRIPTION  In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care.FACULTY BIOSDr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois.  This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32

This educational podcast will provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of Triple-negative breast cancer (TNBC).   Launch Date: November 9, 2023Release Date: November 9, 2023Expiration Date: October 31, 2024   ACTIVITY DESCRIPTION  In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care.FACULTY BIOSDr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois. This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32

This educational podcast will provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of Triple-negative breast cancer (TNBC).   Launch Date: November 9, 2023Release Date: November 9, 2023Expiration Date: October 31, 2024   ACTIVITY DESCRIPTION  In this podcast, Drs. William Gradishar, Yuan Yuan and Rita Nanda will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care.FACULTY BIOSDr. William Gradishar is the Chief of Hematology and Oncology in the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Yuan Yuan is the Director of Breast Cancer Research at Cedar-Sinai Medical Center in Los Angeles, California. Dr. Rita Nanda is the Associate Professor of Medicine at the University of Chicago Medicine in Chicago, Illinois. This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/treatment-progress-in-triple-negative-breast-cancer-improving-disparities-and-outcomes-with-new-approaches-32

See omnystudio.com/listener for privacy information.

BUFFALO, NY- October 25, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Genetic modifiers of p53: opportunities for breast cancer therapies.” Each day our cells encounter a wide range of genomic damage and the p53 protein arbitrates decisions of cell cycle arrest to allow repair of DNA or promote elimination of cells with malignant potential through apoptosis. In this new editorial perspective, researchers Prabin Dhangada Majhi, Aman Sharma and D. Joseph Jerry from the University of Massachusetts, Pioneer Valley Life Sciences Institute and Rays of Hope Center for Breast Cancer Research discuss TP53 mutations. The prevalence of TP53 mutations in nearly all tumors emphasizes its role as a formidable barrier that must be breached to allow oncogenic transformation. Inherited mutations in TP53 are also the primary genetic lesions found in Li-Fraumeni Syndrome (LFS), a familial cancer predisposition characterized by tumors in many tissues. However, tissues are not all equally vulnerable to disruptions in p53 function. Among women with inherited mutations in TP53, breast cancer is by far the most common tumor (Figure 1). Somatic mutations in TP53 are also prevalent in sporadic breast cancers, especially in the triple-negative subtype. The proportion rises to nearly 50% of breast cancers that exhibit impaired function of the p53 pathway based on gene expression signatures as a surrogate biomarker of p53 activity. Therefore, the breast epithelium appears to be uniquely sensitive to alterations in p53 function. “Genomewide association studies (GWAS) have identified over 300 polymorphisms that contribute to breast cancer risk [38–41]. These provide a rich resource of candidate polymorphisms that may modify the consequences of mutations in TP53.” DOI - https://doi.org/10.18632/oncotarget.28387 Correspondence to - D. Joseph Jerry - jjerry@vasci.umass.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28387 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, p53, Li-Fraumeni syndrome, genetic modifiers, breast cancer, DNA repair About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

In our final hour, we were joined by Josh Garvey from Doeren Mayhew as well as Lomas Brown for our weekly Lions/NFL segment. Huge, Josh, and Lomas talked about what they liked from this Lions team last week, what they hope to see this weekend against the Seahawks, gave their picks for all of the NFL games this weekend, and more. We wrapped up the hour talking about the Van Andel Institute and their Bee Brave 5K walk/run happening at Shagbark Farms in Caledonia on October 7th. We were joined in studio by Chris Bartnick, who is the Race Director, and Stefanie Jarmer who is the Assistant Coordinator of the Bee Brave 5K. They talked about the meaning behind this awesome event, discussed the funds they've raised for Breast Cancer Research, filled us in on how you can join, and more. Visit https://runsignup.com/Race/MI/Caledonia/BeeBrave5K to learn more!See omnystudio.com/listener for privacy information.

Today, we got the opportunity to discuss the Van Andel Institute and their Bee Brave 5K walk/run happening at Shagbark Farms in Caledonia on October 7th. We were joined in studio by Chris Bartnick, who is the Race Director, and Stefanie Jarmer who is the Assistant Coordinator of the Bee Brave 5K. They talked about the meaning behind this awesome event, discussed the funds they've raised for Breast Cancer Research, filled us in on how you can join, and more. Visit https://runsignup.com/Race/MI/Caledonia/BeeBrave5K to learn more!See omnystudio.com/listener for privacy information.

We kicked off today's show as we were joined in studio by former Major Leaguer Jon VanderWal. He and Huge talked about the Detroit Tigers at this point in the season, looked ahead to next year and gave their thoughts on how good this team could be, discussed what the roster will look like, and so much more. We were then joined by Jim Comparoni from SpartanMag.com to talk about MSU. He updated us on the Mel Tucker situation, previewed Saturday's game against Washington, and more. We talked about our Detroit Lions in the second hour as Tim Twentyman from DetroitLions.com joined us. Tim and Huge looked back at the win over the Chiefs from last week, talked about some of the stand-out players that they liked, looked ahead to this weekend's game against the Seahawks, and more. We were then joined by Jeremy Reisman from Pride of Detroit to preview the Lions/Seahawks game. Jeremy gave his thoughts on how that game will go, what players he wants to see more from, and he and Huge looked ahead on the schedule as well. In our final hour, we were joined by Josh Garvey from Doeren Mayhew as well as Lomas Brown for our weekly Lions/NFL segment. Huge, Josh, and Lomas talked about what they liked from this Lions team last week, what they hope to see this weekend against the Seahawks, gave their picks for all of the NFL games this weekend, and more. We wrapped up the hour talking about the Van Andel Institute and their Bee Brave 5K walk/run happening at Shagbark Farms in Caledonia on October 7th. We were joined in studio by Chris Bartnick, who is the Race Director, and Stefanie Jarmer who is the Assistant Coordinator of the Bee Brave 5K. They talked about the meaning behind this awesome event, discussed the funds they've raised for Breast Cancer Research, filled us in on how you can join, and more. Visit https://runsignup.com/Race/MI/Caledonia/BeeBrave5K to learn more!See omnystudio.com/listener for privacy information.

In this latest episode of Investigating Breast Cancer, Dr. Nora Disis talks about prevention, treatment, breast cancer vaccine research, and more. Her research focuses on identifying ways to boost the immune response in breast cancer patients to improve chemotherapy outcomes. She is working on discovering new molecular immunologic targets in solid tumors to develop vaccines and cellular therapy for treating and preventing breast cancer. Dr. Disis, a BCRF investigator since 2016, is the Athena Distinguished Professor of Breast Cancer Research and the associate dean for Translational Health Sciences at the University of Washington School of Medicine. She is also the editor-in-chief of JAMA Oncology.

Grace Makari-Judson, MD, is a Professor of Medicine and Chief of the Division of Hematology/Oncology at UMass Chan Medical School, Baystate. She is also the Co-Director of The Rays of Hope Center for Breast Cancer Research, and Chair of the Baystate Health Breast Network and Baystate Regional Cancer Program. She is known as an educator, speaking at forums for both medical and lay audiences and also serves as the Principal Investigator of the Breast Research Registry to provide opportunities for translational research and of numerous clinical trials to enhance care. “You always have to take advantage of relationships, even if you don't necessarily know who those people are that you're collaborating with. You just have to be open to it.” Joined by her own mentee, Dr. Prarthana Bhardwaj who rose to that very challenge, we sat down with Dr. Grace Makari Judson in a discussion on mentorship, taking chances, and staying enthusiastic. Tune in as we dive into the details of mentorship from both sides, gain insight into the specific pitfalls of bad mentoring relationships, and why it's important to learn from your surroundings and take chances when they're afforded. Pearls of Wisdom:   1. Stay open to new opportunities because your path is ever-changing and we can gain so much from learning around us and exploring different experiences. But be sure to instill a foundation of excellence so when that time comes you're ready.  2. A great mentor is somebody who's invested in your growth. They can be sponsors, teachers, or advocates. But be sure to find one that can set an agenda, meet with you frequently, and share beneficial opportunities with you. 3. A great mentee is one who shares enthusiasm about the work and jumps on opportunities presented to them. 4. As physicians, we need to be aware of our own personal biases when caring for patients by reminding ourselves that we're there to empower them. Rather than relating to their issues, empathize and find out what's best for them. 

You Are More Than Just Your Breast Cancer - Hormones and Breast Cancer   Dr. Corinne Menn is a board certified OBGYN and North American Menopause Society Certified Menopause Practitioner. She has a special interest in areas often neglected in women's health: Perimenopause and menopause, the unique needs of female cancer survivors and those at high risk for breast cancer.    Dr. Menn tells us her story of breast cancer dx at age 28, going through menopause three times and is now a pro-hormone educator.   Dr. Menn discusses taking systemic hormones and her journey and how it has changed her life.   Why are doctors and patients so afraid of hormones?   Doctors are so risk adverse – but let's talk about the risks of not treating menopause.   The myth that estrogen causes cancer.   How Tamoxifen works.   Breast cancer nomenclature – estrogen positive – this doesn't mean estrogen caused the cancer – we clarify.   The nuance of being overweight and risk of breast cancer.   The number one killer of women with history of breast cancer is heart disease.   Safety of systemic hormone replacement therapy in breast cancer survivors Article in Breast Cancer Research and Treatment · January 2022 – Dr Bluming -       "Twenty-five studies of HRT after a breast cancer diagnosis, published between 1980 and 2013, are discussed, as are the 20 reviews of those studies published between 1994 and 2021. Only 1 of the 25 studies, the HABITS trial, demonstrated an increased risk of recurrence, which was limited to local or contralateral, and not distant, recurrence. None of the studies, including HABITS, reported increased breast cancer mortality associated with HRT. Even in the HABITS trial, the absolute increase in the number of women who had a recurrence (localized only) associated with HRT administration was 22. It is on the basis of these 22 patients that HRT, with its demonstrated benefits for so many aspects of women's health, is being denied to millions of breast cancer survivors around the world."   The problem with the HABITS trial.   Why are we scaring women so much about breast cancer?   Who is the right breast cancer survivor to start hormones? A good candidate?   Are we overtreating with aromatase inhibitors? Podcast partnership today: Always Discreet https://www.instagram.com/alwaysdiscreet/   Bluming AZ. Hormone Replacement Therapy After Breast Cancer: It Is Time. Cancer J. 2022 May-Jun 01;28(3):183-190.   Young Survival Coalition https://youngsurvival.org/   Vaginal Estrogen for people with a history of breast cancer: https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2021/12/treatment-of-urogenital-symptoms-in-individuals-with-a-history-of-estrogen-dependent-breast-cancer   Dr. Menn is an Alloy Health Medical Advisor and Prescriber www.myalloy.com http://www.drmenn.com/ https://www.instagram.com/drmennobgyn https://www.tiktok.com/@drmennobgyn https://www.facebook.com/drmenn

Australian raised Toby Rand, is a Los Angeles based singer/songwriter and recording artist. Toby currently sings for the band Radio XX. RAND starred as a lead, in the hit “Broadway” musical ROCKTOPIA. Rocktopia toured the USA extensively during 2020. Rand co-founded new band ASHENMOON with Garry Beers (INXS) and Jimmy Khoury (Beth Hart). Their music derives from electronic pop of INXS fused with anthemic classic rock n roll. AshenMoon's debut record release is due early 2020. Rand's primary artistry is his solo project Toby Rand and The FutureKind. This music is a blend of raw, gut-wrenching vocals with anthemic sonics, live instrumentation and beautiful strings of the Hamburg (Germany) symphony orchestra. In 2006, RAND became household name for his appearance on the CBS TV show Rockstar: Supernova with Tommy Lee, Jason Newstead, Gilby Clarke and Dave N​avarro. The show was seen by over 20million viewers each week and ended with RAND as runner-up and signed record deal. As a result, RAND has a rich musical background and extensive touring experience across the globe with his (award-winning) band, JUKE KARTEL. Juke Kartel had numerous songs on charts around the world and tours with SLASH, Rockstar Supernova, Nickelback, Linkin Park, OZZY Osborne and many more. His voice and music are heard frequently in film and television. RAND is also involved in philanthropy. He uses his writing to support international Breast Cancer Research, the youth of Los Angeles, and his children's animation projects, ‘Pom Pom Crew' and ‘Eco Giraffe' Co-writing music with Philippa Pomeranz for said animations, Rand is inspired by encouraging children to live with love, positivity, social and environmental awareness. --- Support this podcast: https://anchor.fm/dadcastco/support

Australian raised Toby Rand, is a Los Angeles based singer/songwriter and recording artist. Toby currently sings for the band Radio XX. RAND starred as a lead, in the hit “Broadway” musical ROCKTOPIA. Rocktopia toured the USA extensively during 2020. Rand co-founded new band ASHENMOON with Garry Beers (INXS) and Jimmy Khoury (Beth Hart). Their music derives from electronic pop of INXS fused with anthemic classic rock n roll. AshenMoon's debut record release is due early 2020. Rand's primary artistry is his solo project Toby Rand and The FutureKind. This music is a blend of raw, gut-wrenching vocals with anthemic sonics, live instrumentation and beautiful strings of the Hamburg (Germany) symphony orchestra. In 2006, RAND became household name for his appearance on the CBS TV show Rockstar: Supernova with Tommy Lee, Jason Newstead, Gilby Clarke and Dave N​avarro. The show was seen by over 20million viewers each week and ended with RAND as runner-up and signed record deal. As a result, RAND has a rich musical background and extensive touring experience across the globe with his (award-winning) band, JUKE KARTEL. Juke Kartel had numerous songs on charts around the world and tours with SLASH, Rockstar Supernova, Nickelback, Linkin Park, OZZY Osborne and many more. His voice and music are heard frequently in film and television. RAND is also involved in philanthropy. He uses his writing to support international Breast Cancer Research, the youth of Los Angeles, and his children's animation projects, ‘Pom Pom Crew' and ‘Eco Giraffe' Co-writing music with Philippa Pomeranz for said animations, Rand is inspired by encouraging children to live with love, positivity, social and environmental awareness. --- Support this podcast: https://anchor.fm/dadcastco/support

Videos: A.I. Is Making it Easier to Kill (You). Here's How. | NYT (10:00) Disturbing simulation shows power, terror of killer robots (7:46) Fear Psychosis and the Cult of Safety – Why are People so Afraid? (13:25)   Peanuts Linked to Lower Breast Cancer Risk Washington University in St. Louis & Harvard University, October 22, 2022 Girls ages 9 to 15 who regularly ate peanut butter or nuts were 39 percent less likely to develop benign breast disease by age 30, according to a new study. Benign breast disease, although noncancerous, increases risk of breast cancer later in life. “These findings suggest that peanut butter could help reduce the risk of breast cancer in women,” says senior author Graham Colditz, professor of surgery at Washington University School of Medicine and associate director for cancer prevention and control at Siteman Cancer Center at Barnes-Jewish Hospital. Published in the journal Breast Cancer Research and Treatment, the findings are based on the health histories of 9,039 US girls enrolled in the Growing Up Today Study . When the study participants were 18 to 30 years old, they reported whether they had been diagnosed with benign breast disease that had been confirmed by breast biopsy. Participants who ate peanut butter or nuts two times each week were 39 percent less likely to have developed benign breast disease than those who never ate them. The study's findings suggest that beans, lentils, soybeans, and corn also may help prevent benign breast disease, but consumption of these foods was much lower in these girls so the evidence was weaker. Past studies have linked peanut butter, nut, and vegetable fat consumption to a lower risk for benign breast disease. However, participants in those studies were asked to recall their high school dietary intakes years later. Perinatal Brain DHA Concentration Has a Lasting Impact on Cognition National Institute on Alcohol Abuse and Alcoholism October 20, 2022 A new study on Proteomics is now available. According to news out of Bethesda, Maryland, research stated, “Premature infants are deprived of prenatal accumulation of brain docosahexaenoic acid [DHA (22: 6n-3)], an omega-3 fatty acid [omega-3 FA (n-3 FA)] important for proper development of cognitive function. The resulting brain DHA deficit can be reversed by omega-3 FA supplementation.” “The objective was to test whether there is a critical period for providing omega-3 FA to correct cognitive deficits caused by developmental omega-3 FA deprivation in mice. Twelve timed-pregnant mice were fed an omega-3 FA-deficient diet containing 0.04% a-linolenic acid, and their offspring were fed the same deficient diet (Def group) or changed to an omega-3 FA-adequate diet containing 3.1% ALA at 3 wk, 2 mo, or 4 mo of age. In parallel, 3 E14 pregnant mice were fed the adequate diet and their offspring were fed the same diet (Adeq group) throughout the experiment. Brain FA composition, learning and memory, and hippocampal synaptic protein expression were evaluated at 6 mo by gas chromatography, the Morris water maze test, and western blot analysis, respectively. Maternal dietary omega-3 FA deprivation decreased DHA by > 50% in the brain of their offspring at 3 wk of age. The Def group showed significantly worse learning and memory at 6 mo than those groups fed the adequate diet. These pups also had decreased hippocampal expression of postsynaptic density protein 95 (43% of Adeq group), Homer protein homolog 1 (21% of Adeq group), and synaptosome-associated protein of 25 kDa (64% of Adeq group). Changing mice to the adequate diet at 3 wk, 2 mo, or 4 mo of age restored brain DHA to the age-matched adequate concentration. However, deficits in hippocampal synaptic protein expression and spatial learning and memory were normalized only when the diet was changed at 3 wk.” The research concluded: “Developmental deprivation of brain DHA by dietary omega-3 FA depletion in mice may have a lasting impact on cognitive function if not corrected at an early age.” At risk for diabetes? Cut the carbs, says new study Tulane University, October 26, 2022 While low-carb diets are often recommended for those being treated for diabetes, little evidence exists on whether eating fewer carbs can impact the blood sugar of those with diabetes or prediabetes who aren't treated by medications. Now, according to new research from Tulane University, a low-carb diet can help those with unmedicated diabetes—and those at risk for diabetes—lower their blood sugar. The study, published in the journal JAMA Network Open, compared two groups: one assigned to a low-carb diet and another that continued with their usual diet. After six months, the low-carb diet group had greater drops in hemoglobin A1c, a marker for blood sugar levels, when compared with the group who ate their usual diet. The low-carbohydrate diet group also lost weight and had lower fasting glucose levels. “The key message is that a low-carbohydrate diet, if maintained, might be a useful approach for preventing and treating Type 2 diabetes, though more research is needed,” said lead author Kirsten Dorans, assistant professor of epidemiology at Tulane University School of Public Health and Tropical Medicine. The study's findings are especially important for those with prediabetes whose A1c levels are higher than normal but below levels that would be classified as diabetes. Approximately 96 million Americans have prediabetes and more than 80% of those with prediabetes are unaware, according to the CDC. Those with prediabetes are at increased risk for Type 2 diabetes, heart attacks or strokes and are usually not taking medications to lower blood sugar levels, making a healthy diet more crucial. How early fears play a role in future anxiety, depression University of Texas at Dallas, October 26, 2022 A recent imaging study led by a scientist at The University of Texas at Dallas has identified early risk factors linked to children's temperament and a neural process that could foretell whether an individual might develop depression and anxiety in adolescence and early adulthood. The study, published Oct. 26 in JAMA Psychiatry, tracked a cohort of 165 individuals from 4 months old, between 1989 and 1993, through age 26. Dr. Alva Tang, assistant professor of psychology in the School of Behavioral and Brain Sciences and corresponding author of the study, found that people who are more inhibited in early childhood and who also don't respond typically to potential rewards as adolescents are vulnerable to developing depression later in life, more so than anxiety. When babies are exposed to novel objects, people or situations, some react positively and approach them without fear, whereas others respond with wariness or avoidance. This differentiation defines uninhibited versus inhibited behavior. “We know that inhibited children are more likely to have anxiety disorders later, particularly social anxiety, that begins in late childhood to adolescence,” Tang said. “Less has been known about depression, which generally has a later onset, in young adulthood. But we do know that people who have had an anxiety disorder are 50% to 60% more likely to have depression later in life, so inhibited children should have higher risk for depression as well.” The researchers found that the association between inhibition at 14 to 24 months of age and worsening depressive symptoms from ages 15 to 26 was present only among those who also showed blunted activity in the ventral striatum as adolescents. There was no similar association with anxiety. “We found that behavioral inhibition was related to worsening depressive symptoms into adulthood. This supports the assertion that this temperament shows a stronger relation to developing anxiety in adolescence, but in adulthood it is tied more strongly to depression. However, not all inhibited children develop anxiety or depression,” Tang said. “It was particularly the inhibited children who showed blunted striatal activity who were more likely to become more depressed in young adulthood.” Pressure chamber therapy is effective in the functional improvement of autism, study finds Tel-Aviv University (Israel), October 26, 2022 A new Tel Aviv University study succeeded in significantly improving social skills and the condition of the autistic brain through pressure chamber therapy. The study was conducted on animal models of autism. In it, the researchers identified changes in the brain, including a reduction in neuroinflammation, which is known to be associated with autism. Moreover, a significant improvement was found in the social functioning of the animal models treated in the pressure chamber. The study's success has many implications regarding the applicability and understanding of treating autism using pressure chamber therapy. Fischer and Barak explain that hyperbaric medicine is a form of therapy in which patients are treated in special chambers where the atmospheric pressure is higher than the pressure we experience at sea level, and in addition are delivered 100% oxygen to breathe. Dr. Barak says that “the medical causes of autism are numerous and varied, and ultimately create the diverse autistic spectrum with which we are familiar. About 20% of autistic cases today are explained by genetic causes, that is, those involving genetic defects, but not necessarily ones that are inherited from the parents.” “Despite the variety of sources of autism, the entire spectrum of behavioral problems associated with it are still included under the single broad heading of ‘autism,' and the treatments and medications offered do not necessarily correspond directly to the reason why the autism developed.” Dr. Barak says that they “discovered that treatment in the oxygen-enriched pressure chamber reduces inflammation in the brain and leads to an increase in the expression of substances responsible for improving blood and oxygen supply to the brain, and therefore brain function. In addition, we saw a decrease in the number of microglial cells, immune system cells that indicate inflammation, which is associated with autism. “To our surprise, the findings showed a significant improvement in the social behavior of the animal models of autism that underwent treatment in the pressure chamber compared to those in the control group, who were exposed to air at normal pressure, and without oxygen enrichment.” Study reveals connection between microbiome and autoimmune disorders University of Calgary, October 23, 2022 Published in Cell, a study by Santamaria and Kathy McCoy, PhD, from the University of Calgary's Cumming School of Medicine (CSM) reveals a new mechanism in the gut microbiome that regulates pro- and anti-inflammatory cells. “We found that a protein expressed by gut bacteria called Bacteroides works to prevent IBD by rapidly recruiting white blood cells to kill a cell of the immune system that is responsible for orchestrating inflammatory bowel disease (IBD),” says McCoy. “We think that this mechanism is likely involved in preventing most people from developing IBD.” However, there is a flipside to the protein's call for help. “In some people, the white blood cells overreact to the presence of the IBD bacteria. This is what causes problems like IBD—it's not the bacteria itself, but the immune system's severe reaction triggered by the protein. These same overstimulated white blood cells are also the cells that cause other autoimmune disorders like diabetes,” says Santamaria. “This discovery demonstrates the effect the gut microbiome has on the immune system and unearths a novel mechanism via which changes in the gut microbiome can increase the risk of autoimmune disorders. While we looked specifically at IBD, it is likely there are many proteins in the gut that contribute to the development of other autoimmune disorders via similar mechanisms.”